Additional Information

Description

Apretude (Cabotegravir) 600 mg/mL injection is a long-acting, extended-release injectable suspension indicated for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection. It is intended for use in at-risk adults and adolescents weighing at least 35 kg. This medication is administered intramuscularly in the gluteal muscle and provides protection against HIV-1 for up to two months with each dose.

The drug works by inhibiting the integrase enzyme required for HIV replication. By preventing the integration of viral DNA into the host genome, cabotegravir stops the virus from replicating. When used as part of a complete PrEP regimen, Apretude significantly reduces the likelihood of acquiring HIV-1 in individuals who are at high risk, providing a long-term preventive effect.

Each single-dose kit includes 1 vial of Apretude (600 mg/mL), 1 vial adapter, 1 syringe, and 1 injection needle (23 gauge, 1-1/2 inch) for gluteal intramuscular injection. The injection is administered every two months, after an initial loading dose, to maintain efficacy.